logo
  

Sonus Networks Cuts Q1 Guidance; Initiates Company-wide Review Of Cost Structure

Sonus Networks, Inc. (SONS) announced that, for the first quarter ending March 27, 2015, the company now expects its revenue to be in the range of $47 million to $50 million compared to previous guidance of $74 million. First quarter non-GAAP loss per share is expected to be in the range of $0.29 to $0.34 compared to previous guidance of non-GAAP earnings per share of $0.03. GAAP loss per share is currently expected to be in the range of $0.45 to $0.50.

The company currently anticipates that revenue for the full year will be up to 25% below the midpoint of its previous annual guidance of $326 million to $330 million.

Sonus also announced that it has initiated a company-wide review of its cost structure. The company no longer expects to receive certain orders in the current quarter that had been expected to be received at the back end of the first quarter, and believes its planned cost reduction initiatives will help better align the cost structure in light of these longer decision cycles.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
While reporting financial results for the first quarter on Wednesday, medical devices company Boston Scientific Corp. (BSX) raised its adjusted earnings and net sales growth guidance for the full-year 2024. For fiscal 2024, the company now projects earnings in a range of $1.43 to $1.48 per share and... Shares of Roche Holding AG were losing around 3 percent in Switzerland after the drug major reported weak sales in its first quarter and confirmed fiscal 2024 outlook. Excluding COVID-19-related products, quarterly sales increasedy 7 percent. For fiscal 2024, Roche continues to expect an increase in group sales in the mid single digit range at constant exchange rates. Dr. Reddy's Laboratories Ltd. is recalling six lots of Sapropterin Dihydrochloride Powder for Oral Solution 100 mg to the consumer level. According to the U.S. Food and Drug Administration, the recall was due to powder discoloration in some packets leading to decreased potency.

This week, we feature Nigeria’s combat with meningitis, Hostile takeover bid for Vanda Pharma, US opioid crisis, Sammy’s Milk’s safety concerns, and X4’s Mavorixafor’s fast-track status.

View More Videos
Follow RTT